Press and media

Razumna runs a small media-relations function for journalists covering the modafinil category, cognitive-performance compounds, the grey-zone direct-import economy, and adjacent regulatory topics. Operational facts available on request.

Press inquiries

Email support@razumna.com with subject line “Press.” Response within one business day.

What razumna will and will not comment on

• Will: Factual questions about sourcing posture, pricing structure, shipping operations, and customer-experience policies. Confirm or correct specific claims about the company. Provide context on category dynamics razumna observes.
• Will not: Make medical claims, comment on individual customer cases (privacy), confirm or comment on persona accounts operated for marketing.
• Off-the-record / background: Available case by case for journalists covering the category seriously. Default is on-the-record.

Press kit

Brand assets, founder bio, pricing/sourcing fact sheet, operational scale references, available on request to verified media. Contact via the email above with affiliation and topic.